16 completed, 3 terminated, 2 recruiting, 1 not yet recruiting. 22 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 22 | Completed 16, Terminated 3, Recruiting 2, Not yet recruiting 1 |
Follow Mixed Dyslipidemia: new trials by email Literature Review of Mixed Dyslipidemia trials Research Report on Mixed Dyslipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Bempedoic acid, Ezetimibe, Rosuvastatin - Coronary Atherosclerosis, Mixed Dyslipidemia | Phase 3 | Not yet recruiting | Daiichi Sankyo | 103 | 2026-09-30 | 2026-09-29 |
| Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days Obicetrapib 10 mg/Bempedoic Acid Placebo, Bempedoic Acid 180mg/Placebo Obicetrapib - Mixed Dyslipidemia, Hypercholesterolaemia | Phase 3 | Recruiting | A. Menarini International Licensing S.A. | 426 | 2026-05-06 | 2026-06-09 |
| Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A DW5421A, DW5421B Placebo, DW5421B - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Completed | Daewon Pharmaceutical Co., Ltd. | 184 | 2025-04-21 | 2026-03-06 |
| A Study to Evaluate the Efficacy and Safety of AD-218 AD-218, AD-218A - Mixed Dyslipidemia | Phase 3 | Recruiting | Addpharma Inc. | 520 | 2022-07-27 | 2025-02-05 |
| Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia evolocumab, placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Terminated | Amgen | 259 | 2019-05-09 | 2023-03-27 |
| Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia Evolocumab, Placebo to Evolocumab - Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Completed | Amgen | 424 | 2016-05-17 | 2018-08-31 |
| Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen Evolocumab AMD, Evolocumab AI/pen - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Completed | Amgen | 164 | 2013-07-11 | 2022-11-30 |
| Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen Evolocumab Pre-filled Syringe, Evolocumab AI/pen - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Completed | Amgen | 149 | 2013-04-18 | 2018-11-29 |
| Bezafibrate Plus Berberine in Mixed Dyslipidemia Berberine, Bezafibrate, Berberine plus Bezafibrate - Mixed Dyslipidemia | Phase 3 | Completed | University of Guadalajara | 36 | 2013-04-01 | 2023-02-24 |
| Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM) - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1139 | 2011-05-01 | 2019-02-06 |
| Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) Extended-release niacin/laropiprant (ERN/LRPT), Placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1173 | 2011-03-01 | 2024-05-22 |
| Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood ABT-335, placebo, atorvastatin - Dyslipidemias, Coronary Heart Disease | Phase 3 | Completed | Abbott | 543 | 2008-02-01 | 2011-06-13 |
| Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) Comparator: simvastatin, niacin (+) laropiprant, Comparator: atorvastatin calcium - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1216 | 2007-07-01 | 2015-03-10 |
| MK-0524B Lipid Study (MK-0524B-063) Comparator: simvastatin, MK-0524A, Placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2414 | 2007-06-15 | 2019-02-06 |
| A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia ABT-335, rosuvastatin calcium, simvastatin - Mixed Dyslipidemia | Phase 3 | Completed | Abbott | 310 | 2007-06-01 | 2012-01-20 |
| An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) Niacin ER/Simvastatin Tablets, atorvastatin - Hyperlipidemia, Mixed Dyslipidemia | Phase 3 | Completed | Abbott | 199 | 2007-04-01 | 2011-06-13 |
| Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin - Dyslipidemia, Coronary Heart Disease | Phase 3 | Completed | Abbott | 1911 | 2006-09-01 | 2009-07-23 |
| Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood ABT-335, Atorvastatin, Placebo - Mixed Dyslipidemia, Coronary Heart Disease | Phase 3 | Completed | Abbott | 613 | 2006-03-01 | 2009-06-03 |
| Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood ABT-335, Simvastatin, Placebo - Dyslipidemia, Coronary Heart Disease | Phase 3 | Completed | Abbott | 657 | 2006-03-01 | 2009-06-03 |
| Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood ABT-335, Rosuvastatin Calcium, Placebo - Dyslipidemia, Coronary Heart Disease | Phase 3 | Completed | Abbott | 1445 | 2006-03-01 | 2009-06-10 |
Showing 20 of 22. Sign in to see all of them.
Hypercholesterolemia (9) · Dyslipidemias (6) · Coronary Disease (5) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Hyperlipidemias (1)
Lipid Metabolism Disorders (15) · Metabolic Diseases (15) · Nutritional and Metabolic Diseases (15) · Dyslipidemias (9) · Hyperlipidemias (9) · Cardiovascular Diseases (6) · Heart Diseases (6) · Myocardial Ischemia (6) · Vascular Diseases (6) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Coronary Disease (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1)
Atorvastatin (7) · 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (6) · Simvastatin (6) · Rosuvastatin Calcium (4) · evolocumab (4) · MK-0524 (3) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (2) · Ezetimibe (2) · Fenofibrate (2) · Fluvastatin (2) · fenofibric acid (2) · Berberine (1) · Bezafibrate (1) · Niacin (1) · Simcor (1)
Abbott (7) · Amgen (4) · Merck Sharp & Dohme LLC (4) · Novartis (2) · A. Menarini International Licensing S.A. (1) · Addpharma Inc. (1) · Daewon Pharmaceutical Co., Ltd. (1) · Daiichi Sankyo (1) · University of Guadalajara (1)
United States (10) · Canada (3) · China (2) · Italy (2) · Mexico (2) · South Korea (2) · Spain (2) · Belgium (1) · Germany (1) · Poland (1) · Switzerland (1) · United Kingdom (1)
Kyu Chang Won, M.D., Ph.D (1) · Maureen Kelly, MD (1) · Roopal Thakkar, MD (1)
PMID 18783301, PMID 20136164, PMID 20573750, PMID 22263674, PMID 18996523, PMID 19995098, PMID 20518948, PMID 20934572, PMID 21174145, PMID 21401833, PMID 22500948, PMID 27066336, PMID 30953107, PMID 36435949
2025 (2), 2015 (1)